Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852975 | 0.75 | POLB (0.40) | KMT2AKDM4ETDP1LMNAHTT | |
| SCHEMBL14182015 | 0.75 | NPSR1 (0.38) | KMT2AL3MBTL1KDM4ETDP1LMNA | |
| SCHEMBL6951347 | 0.74 | CA12 (0.38) | KMT2AL3MBTL1KDM4ETDP1LMNA | |
| SCHEMBL1441268 | 0.73 | KCNH3 (0.41) | SLC2A1LMNAALDH1A1 | |
| SCHEMBL3217738 | 0.73 | MAPT (0.42) | KMT2AKDM4ETDP1LMNAHTT | |
| SCHEMBL6947506 | 0.73 | CA12 (0.47) | L3MBTL1SLC2A1KDM4ETDP1ALDH1A1 | |
| SCHEMBL7711293 | 0.72 | SLC2A1 (0.49) | KMT2AL3MBTL1SLC2A1KDM4ETDP1 | |
| SCHEMBL4638849 | 0.71 | LMNA (0.34) | KDM4ETDP1LMNAHTTALDH1A1 | |
| SCHEMBL6773271 | 0.71 | KMT2A (0.34) | KMT2AL3MBTL1SLC2A1KDM4ETDP1 | |
| Bromide SCHEMBL4638146 | 0.70 | LMNA (0.33) | KDM4ETDP1LMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1102587-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6458814-B1 | VITRONECTIN RECEPTOR ANTAGONISTS AND ARE USEFUL IN THE TREATMENT OF OSTEOPOROSIS: TREATMENT OF INFLAMMATION, CANCER AND CARDIOVASCULAR DISORDERS, SUCH AS ATHEROSCLEROSIS AND RESTENOSIS, AND DISEASES WHEREIN BONE RESORPTION IS A FACTOR, | SMITHKLINE BEECHAM CORPORATION | 2002-10-01 | — | — | US | disclosed |
| EP-1102587-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007544-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-17 | — | — | WO | disclosed |